Merck & Co., Inc. (ETR:6MK)
Germany
· Delayed Price · Currency is EUR | Market Cap | 177.50B |
| Revenue (ttm) | 59.14B |
| Net Income (ttm) | 16.13B |
| Shares Out | n/a |
| EPS (ttm) | 6.36 |
| PE Ratio | 11.00 |
| Forward PE | 9.08 |
| Dividend | 2.93 (4.16%) |
| Ex-Dividend Date | Mar 17, 2025 |
| Volume | 2,812 |
| Average Volume | 3,305 |
| Open | 70.70 |
| Previous Close | 70.50 |
| Day's Range | 70.20 - 71.50 |
| 52-Week Range | 65.50 - 125.60 |
| Beta | 0.44 |
| RSI | 53.68 |
| Earnings Date | Jul 29, 2025 |
About Merck & Co.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The company offers human health pharmaceutical for various areas, including oncology, vaccines, hospital acute care, cardiovascular, virology, neuroscience, and diabetes under the Keytruda, Welireg, Gardasil, ProQuad, M−M−R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janu... [Read more]
Financial Performance
In 2024, Merck & Co.'s revenue was $64.17 billion, an increase of 6.74% compared to the previous year's $60.12 billion. Earnings were $17.12 billion, an increase of 4589.59%.
Financial numbers in USD Financial StatementsNews
Merck Animal Health Receives EU CVMP Positive Opinion for NUMELVI (atinvicitinib) Tablets for Dogs
Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced that the European Medicines Agen...
Merck Animal Health Receives EU CVMP Positive Opinion for NUMELVI™ (atinvicitinib) Tablets for Dogs
RAHWAY, N.J.--(BUSINESS WIRE)--Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced t...
5 stocks to consider right now amid volatility and uncertainty: Portfolio manager
Market volatility can be scary for investors, but it can also bring opportunity. In the video above, Kovitz Investment Group portfolio manager John Buckingham explains why investors should be "embraci...
RFK Jr’s new vaccine advisor has reportedly served as expert witness against Merck vaccine
Exclusive: Kennedy's new vaccine adviser was expert witness against Merck vaccine
One of the new vaccine advisers picked by U.S. Health Secretary Robert F. Kennedy Jr. has earned thousands of dollars as an expert witness in litigation against Merck's Gardasil vaccine, court records...
Merck begins late-stage trial for single dose dengue vaccine
Merck Presents Results on Efficacy and Safety of Enpatoran in Systemic Lupus Erythematosus (SLE) at EULAR 2025
DARMSTADT, Germany--(BUSINESS WIRE)--Not intended for UK-, US- or Canada-based media Merck, a leading science and technology company, today announced the presentation of detailed results from Cohort B...
Merck Initiates Phase 3 Study Evaluating Dengue Vaccine Candidate
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of the MOBILIZE-1 Phase 3 clinical trial evaluating the safety, immunogenicity and efficacy of a...
Merck Initiates Phase 3 Study Evaluating Dengue Vaccine Candidate
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of the MOBILIZE-1 Phase 3 clinical trial evaluating the safety, i...
Merck rival Summit draws a rare sell-equivalent rating
World Bank Slashes Global Growth Forecast To Lowest Since 1960s Amid Trump Tariffs: 'If The Right Policy Actions Are Taken...'
The World Bank has significantly reduced its 2025 global growth forecast, pointing to the escalating trade tensions and policy uncertainty, particularly due to the wide-ranging tariffs imposed by U.S....
Merck: Best Case For Option Collars We'll Ever See
Currently, Merck stock shows potential for another collar setup, with defined risk and reward, though I haven't executed a new trade yet. Read why MRK is a Buy.
Drug pricing reform talks with US government lack clarity, industry executives say
Talks with the Trump administration about lowering U.S. drug prices have so far not provided clarity on when and how reduced prices will be implemented, top executives from Eli Lilly and Merck said at...
Merck & Co., Inc. (MRK) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript
5 Ideal 'Safe' Buys From June Fortune Return On Leadership Screen
Coincident to the June 5, 2025 annual launch of their Fortune 500, Fortune also partnered with Indiggo to measure Return On Leadership, called the ROL100. Arnold research focused on those 100 using YC...
RFK Jr.'s firing of CDC vaccine advisors 'circumvents science' and could threaten public health, experts say
Health and Human Services Secretary Robert F. Kennedy Jr. has gutted a key government panel of vaccine advisors, a stunning move that some public health experts say undermines science, disrupts a trus...
Merck CEO addresses RFK Jr.'s removal of all members of CDC's vaccine advisory committee
CNBC's Angelica Peebles reports on news regarding vaccines.
Merck CEO addresses RFK Jr.'s removal of all members of CDC's vaccine advisory committee
CNBC's Angelica Peebles reports on news regarding vaccines.
The Highest-Quality Dividend Contenders By Quality Scores
The article presents the highest-quality Dividend Contenders, companies listed on U.S. exchanges with higher annual dividend payouts for 10-24 consecutive years. I use a quality scoring system with si...
Field: Vaccine fatigue has caused flu vaccination rates to fall slightly
Emily Field, Barclays head of European pharma research, discusses RFK Jr.'s call to overhaul the CDC vaccine panel, vaccine skepticism, and the impact on stocks like Merck amid new RSV vaccine approva...
Merck wins FDA nod for RSV shot for infants, challenging Sanofi/ AstraZeneca
China’s Center for Drug Evaluation Accepts Merck’s Application for Marketing Authorization of Pimicotinib for Treatment of Tenosynovial Giant Cell Tumor
Darmstadt, Germany: First global filing for potentially best-in-class TGCT treatment based on strong positive data from Phase 3 MANEUVER study Potential for pimicotinib to be first systemic TGCT thera...
FDA approves Mercks RSV shot for infants, ramping up competition with Sanofi and AstraZeneca
Merck's shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus.
US FDA approves Merck's RSV antibody for infants
The U.S. Food and Drug Administration on Monday approved Merck's preventive antibody shot to protect infants up to one year of age from respiratory syncytial virus during their first RSV season, the c...
U.S. FDA Approves Merck’s ENFLONSIA (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Born During or Entering Their First RSV Season
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has approved ENFLONSIA (clesrovimab-cfor) for the prevention of res...